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ttp://dx.doi.org/10.1016/j.ajpath.2014.05.023The underlying causes of endometrial cancer (EMC) are poorly understood, and treatment options for
patients with advanced stages of the disease are limited. Mutations in the phosphatase and tensin
homologue gene are frequently detected in EMC. Cyclooxygenase 2 (Cox2) and mammalian target of
rapamycin complex 1 (mTORC1) are known downstream targets of the phosphatase and tensin homo-
logue protein, and their activities are up-regulated in EMC. However, it is not clear whether Cox2 and
mTORC1 are crucial players in cancer progression or whether they work in parallel or cooperatively. In
this study, we used a Cox2 inhibitor, celecoxib, and an mTORC1 inhibitor, rapamycin, in mouse models
of EMC and in human EMC cell lines to explore the interactive roles of Cox2 and mTORC1 signaling. We
found that a combined treatment with celecoxib and rapamycin markedly reduces EMC progression. We
also observed that rapamycin reduces Cox2 expression, whereas celecoxib reduces mTORC1 activity.
These results suggest that Cox2 and mTORC1 signaling is cross-regulated and cooperatively exacerbate
EMC. (Am J Pathol 2014, 184: 2390e2402; http://dx.doi.org/10.1016/j.ajpath.2014.05.023)Supported in part by grants from the National Cancer Institute, NIH
(P01-CA-77839) (S.K.D.) and Ohio Cancer Research Associates (T.D.) and
postdoctoral fellowships from the Japan Society for the Promotion of
Science (J.T.).
Disclosures: None declared.Endometrial cancer (EMC) is the most common gyneco-
logical malignancy among American women.1,2 According
to National Cancer Institute estimates, about 50,000 women
will be diagnosed with EMC in 2013 and approximately
8200 patients are likely to die from it. Underlying causes of
EMC are not clearly understood, and treatment options for
patients with advanced stages are limited.1,2 Several genetic
alterations are associated with EMC.1,2 One of the most
common mutations is in the phosphatase and tensin homo-
logue gene (PTEN ). Mutations of the TP53 gene, which
encodes p53, are also found in EMC and primarily occur in
poorly differentiated carcinomas.1,2
The loss of PTEN results in increased phosphoinositide 3-
kinase (PI3K) activity and thymoma viral proto-oncogene 1
(Akt) activation. Increased levels of phosphorylated (acti-
vated) Akt (pAkt) stimulate cyclooxygenase 2 (Cox2) and
mammalian target of rapamycin complex 1 (mTORC1)
activities.3e9 Heightened Cox2 and mTORC1 signaling arestigative Pathology.
.associated with EMC.9e14 Cox2 is overexpressed in many
solid tumors, and Cox2-derived prostaglandins (PGs), espe-
cially PGE2 via its receptors EP2/EP4, signiﬁcantly contribute
to carcinogenesis.15,16 Interestingly, analogues of rapamycin
and related inhibitors ofmTORC1 signaling are in phase I to II
clinical trials to treat EMC, and the beneﬁcial effects of cel-
ecoxib in cancers are also the subject of current clinical trials
(http://www.clinicaltrials.gov, last accessed July 22, 2014).
Animal models of spontaneously developed cancers are
powerful tools for studying the mechanisms underlying
cancer initiation and progression and for developing treat-
ment strategies. We previously generated mouse models
with conditional uterine deletion of Pten (Ptend/d) or of Pten
mTORC1 and Cox2 in Endometrial Cancerand Trp53 (Pten/Trp53d/d) using the Cre/loxP approach.17
Female mice with ﬂoxed alleles of Pten and/or Trp53
were crossed with males expressing Cre recombinase driven
under the progesterone receptor promoter (Pgr-Cre).18
Ptend/d females spontaneously developed EMC with 100%
penetrance by 30 days of age, and Pten/Trp53d/d females
developed a more aggressive form of this disease by 21 days
of age. Using these mouse models, we previously showed
that pAkt and Cox2 levels are elevated in the uteri of both
Ptend/d and Pten/Trp53d/d mice.17
Here, we show that a downstream component of the
mTORC1 effector pathway is signiﬁcantly up-regulated in
the uteri of these mice. These results suggest that Cox2 and
mTORC1 are associated with EMC. We then examined
whether the Cox2 and mTORC1 pathways are critical in
cancer progression and whether they inﬂuence EMC inde-
pendently or cooperatively. We treated Ptend/d females and
their control littermates (Ptenf/f) with rapamycin (mTORC1
inhibitor) and/or celecoxib (Cox2 inhibitor) by oral gavage
on every alternate day for 29 days, beginning at 30 days of
age. We found that treatment with rapamycin or celecoxib
monotherapy attenuated tumor growth, whereas maximal
reductions in tumor growth and progression were noted in
Ptend/d females receiving both rapamycin and celecoxib. We
also observed a similar reduction in tumor progression in
Pten/Trp53d/d females after combined treatment with rapa-
mycin and celecoxib. Using a mouse EMC cell line estab-
lished from Pten/Trp53d/d uteri and three human EMC cell
lines, we also found that rapamycin reduces Cox2 expres-
sion at the mRNA and protein levels and that celecoxib
reduces mTORC1 activity, suggesting that Cox2 and
mTORC1 activities are cross-regulated and cooperatively
exacerbate EMC. Thus, a combined treatment with cele-
coxib and rapamycin could be an effective therapeutic
strategy for combating EMC.
Materials and Methods
Mice
Mice with uterine deletion of Pten (PtenloxP/loxP/Pgrcre/þ Z
Ptend/d), both Pten and Trp53 (PtenloxP/loxP/Trp53loxP/loxP/
Pgrcre/þZPten/Trp53d/d), or tuberous sclerosis 1 (Tsc1loxP/loxP/
Pgrcre/þZTsc1d/d)weregenerated as describedpreviously.17,19
For experiments, littermatePtend/d andPten/Trp53d/d females on
the mixed background were used. An mTORC1 selective in-
hibitor (rapamycin) and/or aCox2 selective inhibitor (celecoxib)
were suspended in 10% polyethylene glycol 400 (PEG400) and
10% (v/v) polysorbate 80 in water by constant stirring. Mice
were treated with vehicle (10% PEG400 and 10% polysorbate
80), 5 mg/kg body weight of rapamycin, 20 mg/kg body weight
of celecoxib, or 5 mg/kg body weight of rapamycin plus 20 mg/
kg body weight of celecoxib, by oral gavage every alternate day
from 30 to 59 days of age.20e29 Stages of the estrous cycle were
identiﬁed by the examination of vaginal smears.Allmice used in
this investigation were housed in barrier facilities in the AnimalThe American Journal of Pathology - ajp.amjpathol.orgCare Facility at Cincinnati Children’s Hospital Medical Center
according to NIH and institutional guidelines for the care and
use of laboratory animals. All protocols were reviewed and
approved by the Institutional Animal Care and Use Committee,
Cincinnati Children’s Research Foundation.
Treatment with Progesterone or Estrogen
To assess the effects of ovarian hormones on uterine
phosphorylated ribosomal protein S6 (pS6) expression, CD1
wild-type (WT) females were ovariectomized and rested for
2 weeks. They were given a single injection of progesterone
(P4, 2 mg/mouse, s.c.) or 25 or 100 ng estradiol-17b (E2).
30
The control group of mice received only the vehicle (oil).
Mice were euthanized after 12 hours, and uteri were
collected for immunohistochemistry (IHC) analysis.
Scoring Cancer Severity
The extent of the carcinoma was subjectively measured
based on the amount of disease in the uterus, as measured by
light microscopic examination of hematoxylin and eosin
stains as well as IHC analysis for cytokeratin 8 (CK8)
(score: 0, no carcinoma; 1, 25%; 2, 26% to 50%; 3, 51%
to 75%; or 4, 76% to 100%) of the endometrium involved
by carcinoma. Myometrial invasion was noted but was not
included in the scoring system.
Establishment and Culture of Mouse EMC Cell Line
Mouse uterine epithelial cells were isolated by following the
previously described methods.30e32 In brief, uteri collected
from 2-month-old Ptend/d or Pten/Trp53d/d mice were cleaned
of fat tissue, slit longitudinally, and cut into pieces 2 to 3mm in
length. Uterine pieces were then washed several times with
phenol redefree Hank’s Balanced Salt Solution (Life Tech-
nologies Corporation, Carlsbad, CA) with 100 mg/mL of
streptomycin, 100 U/mL of penicillin, and 2.5 mg/mL of
amphotericin B (Sigma-Aldrich, St. Louis, MO). Tissues were
digested with 6 mg/mL of dispase (Life Technologies) and 25
mg/mL pancreatin (Sigma-Aldrich) for 1 hour at 4C, 1 hour at
room temperature, and 10 minutes at 37C. After these
digestion steps, tissues were immediately diluted in Hank’s
Balanced Salt Solution containing 10% fetal bovine serum
(FBS) and mixed thoroughly to dislodge the sheet of luminal
epithelial cells. The dispersed cells were collected by centri-
fugation and plated on the dish were coated with Matrigel,
which was diluted to 4with phosphate-buffered saline (PBS)
(BD 354234; BD Biosciences, San Jose, CA). Cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium and Ham’s
F-12 nutrient mixture (1:1) with 10% FBS and antibiotics.
Immunolocalization
Immunoﬂuorescence was performed to localize E-cadherin and
CK8, along with nuclear staining as previously described.332391
Daikoku et alSenescence-Associated b-Gal Staining
Staining of senescence-associated b-gal activity was per-
formed as described previously.21 In brief, cultured cells
were ﬁxed in 0.5% glutaraldehyde in PBS and stained
overnight in PBS (pH 5.5) containing 1 mmol/L MgCl2,
1 mg/mL X-Gal, and 5 mmol/L each of potassium ferricya-
nide and potassium ferrocyanide. Cells were counterstained
with eosin.
Culture of Human EMC Cell Lines
RL95-2was purchased fromATCC (Manassas, VA). HEC116
and HEC50B were kindly provided by Hiroyuki Kuramoto
(Kitasato University, Kanagawa, Japan). RL95-2 was cultured
in Dulbecco’s modiﬁed Eagle’s medium and Ham’s F-12
nutrient mixture (1:1), whereas HEC116 and HEC50B were
cultured in Dulbecco’s modiﬁed Eagle’s medium. All culture
media were supplemented with 10% FBS and antibiotics.
Western Blot Analysis
Tissue and cultured cell samples were prepared as previously
described.34 After measuring of protein concentrations, super-
natants were boiled with SDS-PAGE sample buffer for 5 mi-
nutes. Samples were run on 10% to 12% SDS-PAGE gels and
transferred onto polyvinylidene diﬂuoride membranes. Mem-
branes were blocked with 10% milk or 5% bovine serum al-
bumin in Tris-buffered saline Tween20 and probed with
antibodies to S6 and pS6 (Cell Signaling Technology, Inc.,
Beverly, MA), Cox1 (kindly provided by David DeWitt,
Michigan State University, East Lansing, MI), Cox2 (Cayman
Chemical Company, Ann Arbor, MI), Akt (Cell Signaling
Technology, Inc.), pAkt (Cell Signaling Technology, Inc.),Table 1 Antibodies and Applications
Antibody Source
pS6 Cell Signaling Technology, Inc.
pS6 Cell Signaling Technology, Inc.
S6 Cell Signaling Technology, Inc.
mTOR Cell Signaling Technology, Inc.
Raptor Cell Signaling Technology, Inc.
CK8 Developmental Studies Hybridoma Bank
CK8 Developmental Studies Hybridoma Bank
Ki-67 Thermo Fisher Scientific, Inc.
Cleaved caspase 3 Cell Signaling Technology, Inc.
Cleaved caspase 3 Cell Signaling Technology, Inc.
pAkt Cell Signaling Technology, Inc.
Akt Cell Signaling Technology, Inc.
b-actin Santa Cruz Biotechnology, Inc.
Cox1 David DeWitt (East Lansing, MI)
Cox2 Cayman Chemical Company
E-cadherin Cell Signaling Technology, Inc.
Hoeschst 33342 Life Technology Corporation (Carlsbad, CA)
The antibodies are listed along with dilutions used for immunocytochemistry (
NA, not applicable.
2392E-cadherin (Cell Signaling Technology, Inc.), or b-actin
(Santa Cruz Biotechnology, Inc., Dallas, TX), overnight at 4C
(Table 1). After washing, blots were incubated in peroxidase-
conjugated donkey antigoat or donkey antirabbit IgG (Jack-
son ImmunoResearch Laboratories, Inc.,West Grove, PA). All
signals were detected using chemiluminescent reagents (GE
Healthcare, Wauwatosa, WI). S6, Akt, and b-actin served as
loading controls.
IHC Analysis
IHC analysis was performed as previously described.22,34
Tissues were ﬁxed in Protocol Safeﬁx II (Thermo Fisher
Scientiﬁc Inc.) and embedded in parafﬁn. Uterine sections
(6 m) were subjected to immunostaining using antibodies to
pS6 (Cell Signaling Technology, Inc.), mTOR (Cell
Signaling Technology, Inc.), raptor (Cell Signaling Tech-
nology, Inc.), CK8 (Developmental Studies Hybridoma
Bank, Iowa City, IO), Ki-67 (Thermo Fisher Scientiﬁc
Inc.), or active caspase 3 (Cell Signaling Technology, Inc.)
(Table 1). After deparafﬁnization and hydration, sections
were subjected to antigen retrieval by autoclaving in 10
mmol/L sodium citrate solution (pH 6) for 10 minutes. A
diaminobenzidine was used to visualize antigens. Sections
were counterstained with hematoxylin and eosin.
PG Assays
Uterine tissue was collected and analyzed for PG levels
using a modiﬁed method described previously.35 In brief,
approximately 20- to 25-mg frozen tissues were homoge-
nized in 400 mL of PBS (0.1% BHT and 1 mmol/L EDTA)
using a Precellys high-throughput tissue homogenizer
coupled with a Cryolys cooling unit (Bertin Corporation,Catalog number Use Dilution
2211 WB (12% gel) 1:2000
2211 IHC 1:200
2217 WB (12% gel) 1:2000
2983 IHC 1:100
2280 IHC 1:50
TROMA-1 IHC 1:25
TROMA-1 IF/IC 1:200
RM-9106 IHC 1:200
9661 IHC 1:300
9661 IF/IC 1:400
3787 WB (10% gel) 1:1000
9272 WB (10% gel) 1:1000
sc-1615 WB (10% gel) 1:500
NA WB (10% gel) 1:2500
160126 WB (10% gel) 1:5000
3195 IF/IC 1:400
H1399 IF/IC 1:500
IC), immunoﬂuorescence (IF), Western blot (WB) analysis.
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mTORC1 and Cox2 in Endometrial CancerRockville, MD). PGs were then extracted in hexane/ethyl
acetate (1:1) and measured by the liquid chromatography/
tandem mass spectrometry method using the Agilent 1200
series high-performance liquid chromatography system
and tandem quadruple mass spectrometry (6460 series;
Agilent Technologies, Inc., Santa Clara, CA). PGs of in-
terest were chromatographically separated using a Kinetex
3-mm C18 2  100-mm analytic column (Phenomenex,
Inc., Torrance, CA). The mobile phase consisted of 0.1%
formic acid inwater and 0.1% formic acid in acetonitrile using a
linear methanol gradient consisting of 20%B to 40%B for 4
minutes and then stay at 40%B for 8.5 minutes, followed by
changing from 40%B to 90%B in 12 minutes. This was then
increased to 98%B organic concentration over the next 5 mi-
nutes and kept at this condition for an additional 4 minutes to
achieve chromatographicbaseline resolution.Theﬂowratewas
0.4 mL/minute, with a column temperature of 35C. The mass
spectrometer was operated in negative electrospray ionization
mode, with source and gas temperatures at 350C for the
analysis of eicosanoids. PGs were detected and quantiﬁed by
multiple reactionmodemonitoring of the transitions ofPGs and
their relevant internal standards (Cayman Chemical Com-
pany).35 PG levels were normalized against tissue protein
concentrations.
Cell Viability Assay
Mouse EMC (2  103 per well) and RL95-2 human EMC
(1  104 per well) cells were seeded in a 96-well plate.
After culture overnight in Dulbecco’s modiﬁed Eagle’s
medium and Ham’s F-12 nutrient mixture (1:1) with 10%
FBS and antibiotics, the cells were incubated in serum-free
medium containing either 0.2% dimethyl sulfoxide
(DMSO), rapamycin, or celecoxib. 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) colorimetric assays per manufacturer’s
instructions (Promega Corporation, Fitchburg, WI) were
monitored at an absorbance of 490 nm as an index of cell
viability/proliferation.
Cell Cycle Analysis
Mouse EMC cells (1.0 106 per dish) were plated in 100-mm
plates. After culture overnight, the cells were incubated for
2 days in serum-free medium containing either 0.2% DMSO,
rapamycin, or celecoxib. Trypsinized cells were ﬁxed with
ethanol and treated with propidium iodide and RNaseA. Data
were collected and analyzed using a LSRFortessa ﬂow cy-
tometer and FACSDiva version 6.1.3 (BD Immunocytometry
Systems, San Jose, CA) or FlowJo version 9.7.5 (Tree Star Inc.,
Ashland, OR) software.
Apoptosis Assays
Mouse EMC cells (1.0 106 per dish) were plated in 100-mm
plates. After culture overnight, the cells were incubated for 3The American Journal of Pathology - ajp.amjpathol.orgdays in serum-free medium containing either 0.2% DMSO,
rapamycin, or celecoxib. Apoptotic cells were identiﬁed using a
TACS Annexin V-FITC Apoptosis Detection Kit according to
the manufacturer’s instructions (R&D Systems Inc., Minneap-
olis, MN). For this assay, the cells were harvested, washed, and
incubated with annexin V ﬂuorescein isothiocyanate and pro-
pidium iodide. After washing, the cells were analyzed by ﬂow
cytometry. Apoptotic cells were also examined by immunoﬂu-
orescence with anticleaved caspase 3 antibody (Table 1). In
brief, 5 104 mouse EMC cells per well were seeded in 8-well
chamber slides. After overnight culture, the cells were treated
with vehicle (0.2%DMSO), celecoxib, rapamycin, or celecoxib
plus rapamycin, for 6 hours in serum-free culture media. Cells
were ﬁxed in 4% paraformaldehyde/PBS and immunoﬂuores-
cence of cleaved caspase 3 was performed (Table 1).
RNA Extraction and RT-PCR
Uterine tissue or EMC cell samples were prepared and
analyzed as previously described.34,36 In brief, total RNA
was extracted with TRIzol according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA). After DNase treatment
(Ambion Diagnostics Inc., Austin, TX), 1 mg of total RNA
was reverse-transcribed with SuperScript II (Invitrogen).
PCR was performed using primers 50-AGACCATAACC-
CACCACAGC-30 and 50-TACACCAGTCCGTCCCTTTC-30
for mouse Pten; 50-ACAGGACCCTGTCACCGAGACC-30
and 50-GACCTCCGTCATGTGCTGTGAC-30 for mouse
Trp53; 50-ACACACTCTATCACTGGCACC-30 and 50-
TTCAGGGAGAAGCGTTTGC-30 for mouse Ptgs2; 50-
AGGAGATGGCTGCTGAGTTGG-30 and 50-AATCTGA-
CTTTCTGAGTTGCC-30 for mouse Ptgs1; 50-GTGGGC-
CGCCCTAGGCACCAG-30 and 50-CTCTTTGATGTCAC-
GCACGATTTC-30 for mouse Actb; 50-TGGGAAGCCTT-
CTCTAACCTCTCCT-30 and 50-CTTTGACTGTGGGAG-
GATACATCTC-30 for human PTGS2; 50-GAAGAAGT-
GGTGCGTAGGGA-30 and 50-AAGGATTTGGTGTGAG-
CGAT-30 for GUSB.
Statistical Analysis
The Student’s t-test was performed to determine the statis-
tical signiﬁcance of the differences between groups, and the
results were reported as statistically signiﬁcant if the P <
0.05 in individual tests.
Results
Endometrial Deletion of Pten or Both Pten and Trp53
Up-Regulates Epithelial mTORC1 Signaling
mTORC1 is a downstream target of Akt signaling, which is
activated by Pten deletion and is associated with EMC.9e11
Activation of mTORC1 signaling induces ribosomal protein
S6 phosphorylation and is a reliable downstream indicator
of heightened mTORC1 signaling.372393
Daikoku et alWe examined the status of pS6 in Ptend/d uteri. We found
increased levels of pS6 in Ptend/d uteri compared with those in
littermate ﬂoxed uteri at 21 and 30 days of age (Figure 1A and
Supplemental Figure S1). However, the levels of pS6 in total
uterine extracts were similar between ﬂoxed and Ptend/d fe-
males at 60 and 90 days of age (Figure 1A and Supplemental
Figure S1). Interestingly, we observed a higher intensity of
pS6 immunolocalization primarily in the uterine epithelia of
Ptend/d uteri at both 30 and 90 days of age, whereas its
expression in ﬂoxed uteri was very low and diffused throughout
the endometrium (Figure 1C). pS6 is expressed in both the
stroma and epithelium in ﬂoxed uteri and is regulated by pro-
gesterone and estrogen (Supplemental Figure S2). Thus, dif-
ferences in pS6 levels between ﬂoxed and Ptend/d uteri were
difﬁcult to assess by Western blot analysis after the estrous
cycle had started because of the dilution of the protein extractsFigure 1 mTORC1 and Cox2 pathways are highly activated in mouse
EMC. A: Western blot analysis of pS6, an mTORC1 downstream effector, with
Ptenf/f (WT) and Ptend/d uteri. B: pS6 Western blot analysis with Pten/
Trp53f/f (WT) and Pten/Trp53d/d uteri. C: pS6 immunostaining with Ptenf/f
and Ptend/d uteri. D: IHC analysis of mTORC1 components mTOR and raptor.
E: Western blot analysis of Cox2 and PG levels with Ptenf/f and Ptend/d uteri.
S6 and b-actin served as loading control. *P < 0.05 versus WT. Scale
bars Z 400 mm. ge, glandular epithelium; le, luminal epithelium; myo,
myometrium; s, stroma.
2394with heterogeneous cell types. Heightened levels of pS6 were
also observed in Pten/Trp53d/d uteri (Figure 1B). mTOR and
raptor, which are constituents of mTORC1 complex, were
expressed throughout the endometria of both ﬂoxed and Ptend/d
uteri (Figure 1D). These results indicate that mTORC1 function
is stimulated only in Ptend/d uteri, although mTORC1 ma-
chinery exists in both ﬂoxed and Ptend/d uteri.
PGE2 and PGD2 Are Predominantly Produced in Pten
d/d
Uteri
Cox2 is also a downstream target of Akt signaling and is asso-
ciated with EMC. We previously showed that Cox2 expression
is up-regulated in both Ptend/d and Pten/Trp53d/d uteri.17 We
also showed that Cox2 levels are higher in Ptend/d uteri
compared with those in Ptenf/f uteri (Figure 1E).
Cox2-derived PGs are known contributors to cancer
growth.15,16 Thus, we sought to characterize the PG proﬁle in
mouse EMC.We observed that levels of PGE2 and PGD2 were
much higher in Ptend/d uteri than inWT uteri (Figure 1E). High
levels of 6-keto-PGF1a, a stable metabolite of PGI2, were also
noted inWT andPtend/d uteri. Levels of PGF2a, 13,14-dihydro-
15-keto-PGF2a (13-PGF2a), and 13-PGE2 were either very low
or below the detection limits. Cox2 converts arachidonic acid to
PGH2, which is converted to PGE2, PGD2, PGI2, and PGF2a by
their speciﬁc PG synthases. The levels of these individual
metabolites are dependent on the activities of speciﬁc synthases
in the deﬁned tissues/cells. The relative lower levels of PGF2a
suggest that the expression and activity of PGF2a synthase is
limited in the uterus. 13-PGE2 and 13-PGF2a, which are
primary metabolites of PGE2 and PGF2a, are generated by
15-hydroxy-PG dehydrogenase (15-PGDH). Because both
13-PGE2 and 13-PGF2a levels are undetectable in both Pten
f/f
and Ptend/d uteri, and are lower in Ptend/d compared with those
in Ptenf/f uteri, the results suggest that the deletion of Pten
perhaps decreases the expression or activity of 15-PGDH, a
known tumor suppressor in various cancers, including colon,
gastric, and lung cancers.38e40 Taken together, these results
indicate that the Pten deletion not only up-regulates Cox2
expression but also down-regulates 15-PGDH, resulting in
increased levels of PGE2 in Pten
d/d uteri. These results also
suggest that Cox2-derived PGE2 and PGD2 are major players
in EMC. Collectively, both Cox2 and mTORC1 pathways are
activated in mouse EMC as observed in human EMC.13,41
Although Cox2 and mTORC1 signaling are associated with
EMC, it is not known whether they are critical in EMC pro-
gression and whether they work in parallel or cooperatively.
Thus, we then examinedwhether treatment with celecoxib and/
or rapamycin would attenuate EMC growth in mice.
Cox2 and mTORC1 Inhibitors Compromise EMC in Ptend/d
and Pten/Trp53d/d Females
Ptend/d female mice were treated for 29 days with vehicle,
celecoxib, rapamycin, or celecoxib plus rapamycin, starting
at 30 days of age, when these mice develop EMC.17ajp.amjpathol.org - The American Journal of Pathology
mTORC1 and Cox2 in Endometrial CancerAlthough uterine wet weights and sizes were signiﬁcantly
reduced in Ptend/d females after treatment with rapamycin or
celecoxib alone, they were further attenuated by combined
treatment with rapamycin and celecoxib (Figure 2, A and B).
The effects of combined treatment (Cel þ Rap) appear syn-
ergistic because the observed reduction in uterine weight/body
weight with celecoxib and rapamycin treatment is less than
expected. In addition, mTORC1 and Cox2 signaling pathways
can inﬂuence each other to affect speciﬁc function, sug-
gesting that the effects of the combined treatment are syn-
ergistic. We also examined cancer severity by histological
analysis (Figure 2C). Although rapamycin treatment
markedly reduced the severity of EMC in Ptend/d females,
treatment with celecoxib had little effect on cancer severity.
In contrast, all uteri examined after the combined treatment
with celecoxib and rapamycin scored below the highest
severity score of 4. These results indicate that celecoxib
exacerbates the effects of rapamycin on EMC severity.
We also examined whether these treatments affect EMC in
Pten/Trp53d/d female mice. Uterine wet weights, sizes, and
cancer severity were markedly reduced with rapamycin treat-
ment, whereas celecoxib treatment alone had little effect on
these parameters (Figure 3). On the contrary, the combined
treatment with celecoxib and rapamycin showed much
reduction in uterine wet weights and sizes compared to rapa-
mycin treatment alone. Cancer severity was also attenuated
after treatment with both celecoxib and rapamycin, although
this ﬁnding was not signiﬁcant when compared with mice
receiving only rapamycin treatment. We also examined the
effects of celecoxib and rapamycin in Ptenf/f and Pten/Trp53f/fFigure 2 Treatment with celecoxib and/or rapamycin reduces uterine weights
vehicle (10% PEG400 and 10% polysorbate 80), 20 mg/kg body (BD) weight Cox2
(Rap), or celecoxib plus rapamycin (Cel þ Rap), every alternate day from age 30 to
from Ptend/d mice. The center lines are the medians, the boxes encompass 50%
B: Immunostaining of an epithelial marker CK8 and hematoxylin and eosin staining
before treatment and from 60-day-old Ptend/d and Ptenf/f mice with treatment. C: A
of mouse numbers scored to each severity. **P < 0.01, ***P < 0.001, ****P
epithelium; le, luminal epithelium; myo, myometrium; ND, not determined; s, str
The American Journal of Pathology - ajp.amjpathol.orgmice. Although celecoxib treatment alone slightly increased
uterine wet weight compared with that with vehicle treatment,
this change was much less compared to the effects observed in
Ptend/dmice (Supplemental Figure S3). In addition, combined
treatment with celecoxib and rapamycin did not affect the re-
sults of histological examination of the uteri (Figure 2B). All
mice treated with rapamycin and/or celecoxib were of body
weights more or less similar to those in mice receiving vehicle
(Supplemental Table S1). This result suggests that rapamycin
and/or celecoxib treatment does not inﬂuence body weight.
Collectively, these results again indicate that the Cox2 and
mTORC1 pathways cooperatively exacerbate EMC. Because
the long-term use of high doses of Cox2 inhibitors poses
increased cardiovascular risks, and because rapamycin is an
immunosuppressant,20e29 we used lower doses of celecoxib
and rapamycin and used them less frequently. Because of the
different metabolic and clearance rates of drugs in mice and
humans, the doses of the drugs used in this study cannot
directly be compared with those in humans. Notably, we used
lower doses of celecoxib and rapamycin (20 and 5mg/kg body
weight, respectively) every alternate day. With these results in
hand, we next sought to examine the molecular link between
Cox2 and mTORC1 signaling.
Treatment with Celecoxib and/or Rapamycin Reduces
Cell Viability in Pten/Trp53d/d Mouse EMC Cells and in a
Human EMC Cell Line with PTEN Mutation
We established a mouse EMC cell line to examine the effects
of rapamycin or celecoxib on Cox2 or mTORC1 signaling.and cancer severity in Ptend/d mice. Ptend/d female mice were treated with
inhibitor celecoxib (Cel), 5 mg/kg body weight mTORC1 inhibitor rapamycin
59 days. Uteri were collected at the age of 60 days. A: Uterine (UT) weight
of the data points, and the error bars indicate 100% of the data points.
. Uterine histological examination from 30-day-old Ptenf/f and Ptend/d mice
nalysis of cancer severity in Ptend/d mice. Data are expressed as percentages
 0.0001, and *****P < 0.0001. Scale bars Z 400 mm. ge, glandular
oma.
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Daikoku et alEpithelial cells were isolated from both Ptend/d and
Pten/Trp53d/d uteri and were seeded in separate dishes to
establish mouse EMC cell lines. We found that Ptend/d cells
attached to plastic dishes, but stopped growing after a few
rounds of cell splitting or after freezing with 10% DMSO.
In contrast, a Pten/Trp53d/d EMC cell line was successfully
established, and these cells were able to grow after freezing
and thawing. Epithelial cells regrown from frozen stock of
Pten/Trp53d/d EMC cells were stained with epithelial cell
markers E-cadherin and CK8. Epithelial cells from frozen
stock of Ptend/d EMC did not show E-cadherin or CK8
staining, although sections of Ptend/d uteri showed positive
staining for these markers in the epithelium (Supplemental
Figures S4, A and B). The purity of Pten/Trp53d/d cells
was >99% (CK8þ) (Supplemental Figure S5A). The
absence of Pten and Trp53 expressions was conﬁrmed by
RT-PCR (Supplemental Figure S5B). As expected, the
levels of pAkt, Cox2, pS6, and E-cadherin were much
higher in these cells (Supplemental Figure S5C). The
expression of prostaglandin-endoperoxide synthase 2
(Ptgs2), which encodes Cox2, was also conﬁrmed by RT-
PCR (Supplemental Figure S5B).
Because Pten inactivation was shown to induce cellular
senescence through p53 in mouse embryonic ﬁbroblast
cells, we examined senescence-associated b-gal staining
in uterine epithelial cells.42 Interestingly, epithelial cells
isolated from Ptend/d uteri showed the presence of se-
nescent cells, whereas the cells from Pten/Trp53d/d uteri
did not show this activity (Supplemental Figure S4C).Figure 3 Treatment with rapamycin alone or with rapamycin and celecoxi
d mice. Pten/Trp53d/d female mice were treated with vehicle (10% PEG400 and
body (BD) weight rapamycin (Rap), or celecoxib plus rapamycin (Cel þ Rap)
age of 60 days. A: Analysis of uterine (UT) weight from Pten/Trp53d/d mice. T
points, and the error bars indicate 100% of the data points. B: An epithelia
examination from 30-day-old Pten/Trp53f/f and Pten/Trp53d/d mice without a
Trp53d/d mice after treatment. C: Analysis of cancer severity from Pten/Trp53d
each severity. *P < 0.05, **P < 0.01, and ****P < 0.0001. Scale bars: 200
epithelium; s, stroma.
2396Failure to establish a Ptend/d epithelial cell line was
perhaps due to the fragile nature of these cells that are
undergoing senescence. Matrigel support is required to
successfully create a primary culture of uterine epithelial
cells.43 Pten/Trp53d/d cells grew without Matrigel support
after three or four passages and could survive >10 pas-
sages (data not shown).
Our next objective was to better understand the mecha-
nism that drives inhibition of tumor growth when using
rapamycin and celecoxib. We ﬁrst used MTS assay to
evaluate the viability of Pten/Trp53d/d mouse EMC cells.
Rapamycin or celecoxib reduced the viability of Pten/
Trp53d/d EMC cells in a dose-dependent manner (Figure 4,
A and B). Moreover, combined treatment with rapamycin
and celecoxib further reduced cell viability (Figure 4C). We
also used a human RL95-2 EMC cell line with PTEN and
TP53 mutations.44,45 Rapamycin or celecoxib reduced cell
viability of RL95-2 EMC cells in a dose-dependent manner
(Figure 4, D and E). Celecoxib was more effective in
reducing viability in this cell line compared with Pten/
Trp53d/d mouse EMC cells. However, combined treatment
with rapamycin and celecoxib further reduced the cell
viability (Figure 4F). We also used a human HEC50B EMC
cell line without PTEN mutation to examine cell viability by
MTS assay.44,46 In this cell line, rapamycin or celecoxib did
not affect cell viability (Supplemental Figure S6). These
results suggest that rapamycin and celecoxib are speciﬁcally
effective in EMC with Pten mutation or Pten and Trp53
mutations.b together reduces uterine weights and cancer severity in Pten/Trp53d/
10% polysorbate 80), 20 mg/kg body weight celecoxib (Cel), 5 mg/kg
every alternate day from age 30 to 59 days. Uteri were collected at the
he center lines are the medians, the boxes encompass 50% of the data
l marker CK8 and hematoxylin and eosin staining. Uterine histological
ny treatment. Uterine histological examination from 60-day-old Pten/
/d mice. Data are expressed as percentages of mouse numbers scored to
mm (30 days), 400 mm (60 days). ge, glandular epithelium; le, luminal
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mTORC1 and Cox2 in Endometrial CancerRapamycin Attenuates Cell Proliferation, and Celecoxib
Accentuates Apoptosis, in EMC
We next used cell cycle and apoptosis assays by culturing
Pten/Trp53d/d EMC cells in either the absence or presence of
celecoxib, rapamycin, or rapamycin plus celecoxib. Cell
cycle analysis by ﬂow cytometry showed that rapamycin
arrested cells at the G0/G1 phase (Figure 5A), whereas cele-
coxib had little effect on cell cycle. Interestingly, celecoxib
increased the rate of apoptosis, whereas rapamycin did not
show such an effect (Figure 5B and Supplemental Figure S7).
More importantly, the combined treatment with celecoxib
and rapamycin increased the rate of apoptosis compared with
celecoxib alone. These results suggest that although both
rapamycin and celecoxib decrease cell proliferation, cele-
coxib alone increases apoptosis; however, rapamycinFigure 4 Treatment with celecoxib and/or rapamycin reduced cell
viability through apoptosis and/or growth arrest in this mouse EMC cell line
established from Pten/Trp53d/d uteri and in this human EMC cell line with
PTEN and TP53 mutations. Pten/Trp53d/d EMC cells were treated with vehicle
(0.2% DMSO), celecoxib, rapamycin, or celecoxib plus rapamycin for 48 hours
in serum-free culture media. AeC: Cell viability as evaluated by MTS assay.
RL95-2 human EMC cells were treated with vehicle (0.2% DMSO), celecoxib,
rapamycin, or celecoxib plus rapamycin for 72 hours in serum-free culture
media. DeF: Cell viability as evaluated by MTS assay. Data are expressed as
means  SEM (n Z 5). *P < 0.05. MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
The American Journal of Pathology - ajp.amjpathol.orgincreases the rate of apoptosis when combined with cele-
coxib. These ﬁndings were also reﬂected in the Ptend/d and
Pten/Trp53d/d mice treated with celecoxib, rapamycin, or
celecoxib plus rapamycin, as examined by proliferation-
associated nuclear antigen (Ki-67) and active caspase 3
staining (Figure 5, C and D). The assessment of cell prolif-
eration by Ki-67 staining is an indicator of growth, whereas
active caspase 3 staining provides information on the status
of apoptotic cells in tissues. Ki-67epositive cells were
mainly observed in epithelial cells, which transformed into
cancer cells in both Ptend/d and Pten/Trp53d/d uteri
(Figure 5C). The populations of Ki-67epositive cells were
substantially lower in both Ptend/d and Pten/Trp53d/d mice
exposed to rapamycin than in those receiving the vehicle;
celecoxib had little effect on cell proliferation. In contrast,
active caspase 3epositive (apoptotic) cells were more2397
Daikoku et alfrequent in EMC sections of celecoxib-treated mice than in
those from vehicle-treated mice (Figure 5D). Furthermore,
the combined treatment with celecoxib and rapamycin
increased the number of active caspase 3epositive cells
compared with celecoxib treatment alone.
Cox2 and mTORC1 Activities Are Cross-Regulated and
Cooperatively Exacerbate EMC
Our observations suggest that the Cox2 and mTORC1
pathways cooperatively exacerbate EMC, and that celecoxib-2398induced apoptosis was further accelerated by the addition of
rapamycin. Thus, we speculated that Cox2 and mTORC1
signaling pathways are regulated by each other. We therefore
examined the effects of rapamycin or celecoxib on Cox2 or
mTORC1 signaling, respectively. In uteri from Ptend/d
females, treatment with rapamycin every alternate day from
30 to 36 days of age efﬁciently reduced pS6 levels compared
with treatment with vehicle (Figure 6A). Decreased levels of
pS6 were also observed in uteri collected from Ptend/d mice
at 12 hours after a single rapamycin administration
(Supplemental Figure S8A). Treatment with 5 nmol/LFigure 5 Rapamycin mainly attenuates cell
proliferation and celecoxib mainly increases
apoptosis in mouse EMC. A: Cell cycle was analyzed
in Pten/Trp53d/d EMC cells stained with propidium
iodide (PI) and analyzed by ﬂow cytometry. Pten/
Trp53d/d EMC cells were treated with vehicle
(DMSO), celecoxib, rapamycin, or celecoxib plus
rapamycin (Cel þ Rap) for 48 hours in serum-free
media. B: The number of apoptotic cells in Pten/
Trp53d/d EMC cells was determined by ﬂow cytom-
etry using an Annexing V-FITC kit. Pten/Trp53d/d EMC
cells were treated with vehicle (Veh) (0.2% DMSO),
celecoxib (Cel), rapamycin (Rap), or celecoxib plus
rapamycin for 72 hours in serum-free media. C:
Ptend/d and Pten/Trp53d/d EMC samples were stained
with Ki-67 to evaluate cell proliferation in vivo. D:
Ptend/d and Pten/Trp53d/d EMC samples were stained
with active caspase 3 to evaluate apoptosis in vivo.
Uterine samples used Ki-67 and caspase 3 immuno-
staining were derived from mice as described earlier.
Data are expressed as means  SEM (n Z 3) (B).
*P < 0.001. n Z 3 (A). Scale bars Z 800 mm.
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Figure 6 Cox2 and mTORC1 activities are cross-
regulated and cooperatively exacerbate EMC. A and
B:Western blot analysis and relative fold changes of
band intensities. Ptend/d female mice were treated
with vehicle (Veh) (10% PEG400 and 10% poly-
sorbate 80) or 5 mg/kg body weight rapamycin
(Rap) (A) or 20 mg/kg body weight celecoxib (Cel)
(B), every alternate day from age 30 to 36 days.
Quantitatively analyzed band intensities of pS6,
Cox2, and pAkt (A) and Cox2 and pAkt (B) were
normalized against total S6, b-actin, and total Akt,
respectively (A), and b-actin and total Akt,
respectively (B). Western blot analysis(C and D) and
RT-PCR (E) analyses. Pten/Trp53d/d EMC cells
(1 106 per dish) were seeded in a 100-mm dish. C:
After culture overnight, the cells were treated with
vehicle (0.2% DMSO), 5 mmol/L celecoxib, 5 nmol/L
rapamycin, or celecoxib plus rapamycin (C þ R) for
48 hours in serum-free or 1% FBSecontaining
media. D: Ptgs2 expression in RL95-2, HEC116, and
HEC50B human EMC cells. GUSB served as an in-
ternal control. RL95-2 (6  105 per well), HEC116
(3  105 per well), or HEC50B (3  105 per well)
human EMC cells were seeded in a 6-well plate. E:
After culture overnight, the cells were treated with
vehicle (0.2% DMSO), 5 mmol/L celecoxib, 5 nmol/L
rapamycin, or celecoxib plus rapamycin for 48 hours
in serum-free media. b-actin served as a loading
control. *P < 0.05.
mTORC1 and Cox2 in Endometrial Cancerrapamycin for 48 hours also efﬁciently reduced pS6 levels in
both mouse and human EMC cell lines (Figure 6, C and E).
These observations suggest that rapamycin efﬁciently
inhibited mTORC1 activities in our experimental models.
However, there is evidence that suppression of mTORC1 can
induce feedback activation of Akt in other cancers.47,48 Thus,The American Journal of Pathology - ajp.amjpathol.orgwe examined pAkt levels in Ptend/d uteri with and without
rapamycin treatment. We found that pAkt levels were not
altered by rapamycin treatment, although pS6 levels were
reduced (Figure 6A and Supplemental Figure S8A). We also
observed that cells in the Pten/Trp53d/d mouse and human
EMC lines exposed to rapamycin did not alter pAkt levels2399
Daikoku et al(Figure 6, C and E); interestingly, total Akt level increased.
The feedback activation of Akt by rapamycin is induced
through insulin-like growth factor-1 receptor (IGF-R1). FBS,
which includes an IGF-R1 agonist, was used to stimulate this
induction in the cell culture system.47 However, we did not
see Akt activation in Pten/Trp53d/d mouse EMC cells by
rapamycin, even in the presence of 10% FBS (Supplemental
Figure S8B). These results suggest that rapamycin fails to
induce a feedback activation of Akt in EMC and that rapa-
mycin treatment has great potential to attenuate human EMC
resulting from a PTEN mutation. We then examined the
effects of rapamycin on Cox2 levels. We found that Cox2
levels were reduced after rapamycin treatment in Ptend/d uteri
(Figure 6A). This effect was more clear in Pten/Trp53d/d EMC
cells. We also found that rapamycin reduced Cox2, but not
Cox1, expression in mouse EMC cells (Figure 6C;
Supplemental Figure S9, A and B). PTGS2 was expressed in
human EMC cell lines RL95-2 and HEC116 with PTEN
mutation (Figure 6D).44,49 Decreasing PTGS2 mRNA levels
by rapamycin treatment were also observed in RL95-2 cells
(Supplemental Figure S9C). These results suggest that the
mTORC1 pathway regulates Cox2 expression via transcrip-
tion and/or translation. However, this regulation occurred only
in uteri with malignancy. We previously reported that
heightened mTORC1 pathway activity resulting from the
deletion of tuberous sclerosis 1 (Tsc1), a repressor of
mTORC1, did not develop EMC but instead resulted in simple
hyperplasia. Interestingly, we found that Cox2 levels were
similar or even lower in Tsc1-deleted uteri when compared
with those in ﬂoxed uteri (Supplemental Figure S10). This
observation suggests that the mTORC1 signaling regulates
Cox2 expression in EMC cells.
We next examined the effects of celecoxib in Ptend/d uteri
and found that celecoxib numerically reduced the pS6 level,
although the difference was not signiﬁcant compared with
that in vehicle-treated mouse uteri (Figure 6B). This effect
was more clearly evident in mouse Pten/Trp53d/d and
human EMC cell lines RL95-2 and HEC116 with PTEN
mutations. Celecoxib also reduced pS6 levels in EMC cells
(Figure 6, C and E). More importantly, such inhibitory ef-
fects of celecoxib were not observed in EMC cells
(HEC50B) that did not show PTGS2 expression. Notably,
rapamycin plus celecoxib treatment reduced pS6 levels to a
greater extent than did treatment with each alone. These
results suggest that Cox2 and mTORC1 activities are cross-
regulated.Discussion
This investigation highlights that the Cox2 and mTORC1
pathways regulate each other and have a cooperative role in
EMC progression. Thus, the use of a combined treatment with
celecoxib and rapamycin may be an effective therapeutic
strategy for combating human EMC progression. It is inter-
esting that rapamycin can suppress Cox2 levels and that2400celecoxib can suppress pS6 levels (mTORC1 signaling).
These observations add new insight into Cox2 and mTORC1
signaling in cancers, although further investigations are
required to determine whether and how Cox2 and mTORC1
directly regulate each other. The present study also highlights
that rapamycin fails to induce a feedback activation of Akt in
EMC, which is unlike the effect of rapamycin in other cancers.
It is known that estrogen exacerbates EMC development,
especially during the early stages. Indeed, treatment with high
doses of progestin to inhibit unopposed estrogen activity is
common during early stages and has been met with reasonable
success.1 However, the drugs available to treat uterine cancers
are limited. For example, tamoxifen, an antiestrogen
commonly used for breast cancer treatment, has estrogenic
effects in the uterus. Long-term treatment with tamoxifen has
been shown to increase the risk for EMC.1 Although spatio-
temporal expressions of pS6 and Cox2 are regulated by E2 and
P4, we found heightened levels of pS6 and Cox2 in EMC
compared with those in normal uterine epithelium. In general,
treatment with celecoxib and/or rapamycin reduced cancer
severity and uterine weights in mice with EMC, although in-
dividual uterine sizes ﬂuctuated within each treatment group.
This variation may be a reﬂection of the additional complexity
posed by the differential spatiotemporal expressions of each
protein that is regulated by P4 and estrogen; further studies are
necessary to address this issue.
Cox2-derived PGE2 is known to play important roles in
the progression of numerous cancers.15 In this study, we
also observed higher uterine levels of PGE2 in mice with
EMC, which were associated with EMC progression. It will
be interesting to see whether PGE2 can activate the
mTORC1 pathway. Another predominant PG product in
EMC was PGD2. The role of PGD2 remains unclear; how-
ever, some studies have shown that PGD2 inhibits cancer
growth and progression.50,51 It is possible that PGD2 at-
tempts to counter the effects of PGE2 in EMC, because
PGD2 has opposite effects against PGE2 in regulating heart
rate and body temperature during sleep.52 Further investi-
gation is warranted to determine whether PGE2 and PGD2
have antagonistic effects in EMC suppression.
Although rapamycin, its analogues, and celecoxib all
show beneﬁcial effects for the treatment of EMC and other
cancers, there remains the question of how effective these
therapies would be in a clinical setting. The long-term usage
of high doses of Cox2 inhibitors poses increased risks for
cardiovascular complications; meanwhile, long-term use
and high doses of rapamycin increase the risk for immu-
nosuppression. Additionally, the potential for feedback
activation of Akt, which may in turn lead to increased
tumorigenesis, would undermine the effectiveness of rapa-
mycin.47,48 In this study, the treatment schedules composed
of lower dosages and low frequency of use of a combined
rapamycin and celecoxib therapy showed a reduction in
EMC progression. These preclinical studies underline the
importance of further investigation into the role of celecoxib
and rapamycin as a potential treatment strategy for EMC.ajp.amjpathol.org - The American Journal of Pathology
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